Esselte Leitz GmbH & Co KG

EQS-News: Formycon reports results for the first quarter 2023

Retrieved on: 
Thursday, June 1, 2023
Partnership, International, KG, MedImmune, Inc. v. Genentech, Inc., FYB, EBIT, Esselte Leitz GmbH & Co KG, Gesellschaft mit beschränkter Haftung, EBITDA, Euro, Physician, ISIN, CFO, Munich, Security (finance), Tourism

Formycon Group’s revenues increased to a total of Euro 21.5. million in the first quarter of 2023 (Q1/2022: Euro 8.1 million).

Key Points: 
  • Formycon Group’s revenues increased to a total of Euro 21.5. million in the first quarter of 2023 (Q1/2022: Euro 8.1 million).
  • A significant part of revenues resulted from a first milestone payment as part of the commercialization partnership from project FYB202 signed in Q1/2023.
  • „In terms of key figures, the first quarter of 2023 was characterized by various positive special effects.
  • We continue to confirm our guidance for 2023", commented Enno Spillner, CFO of Formycon AG.

EQS-News: Formycon publishes results for financial year 2022

Retrieved on: 
Friday, April 28, 2023
GMP, Trademark, Partnership, International, Half-life, KG, MedImmune, Inc. v. Genentech, Inc., FYB, European Medicines Agency, COVID-19, Tax, EBIT, Genentech, Esselte Leitz GmbH & Co KG, Gesellschaft mit beschränkter Haftung, EMA, EBITDA, Acquisition, Regeneron Pharmaceuticals, Investment, Patient, Ophthalmology, ISIN, United Kingdom, Depreciation, Biosimilar, Development, HGB, FDA, Pembrolizumab, Annual report, Ustekinumab, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Commercial code, Security (finance), Chemical, Cryptocurrency, Generic drug, Fine chemical, Pharmaceutical industry, Euro

The annual report at Group level is published for the first time in accordance with IFRS (International Financial Reporting Standards).

Key Points: 
  • The annual report at Group level is published for the first time in accordance with IFRS (International Financial Reporting Standards).
  • Furthermore, a toxicity study has been initiated, which results are a prerequisite for entering the clinical development phase.
  • On December 31, 2022, the Formycon Group's financial figures had developed as follows: Group revenues, which in addition to Formycon AG also include the fully consolidated subsidiaries Formycon Project 201 GmbH, FYB202 Project GmbH, Formycon Project 203 GmbH, Bioeq GmbH and the 50% stake in Bioeq AG increased to a total of Euro 42.5 million (2021 IFRS: Euro 36.6 million) in the fiscal year 2022.
  • Formycon AG achieved revenues (HGB) of Euro 28.3 million in the financial year 2022 (2021 HGB: Euro 26.5 million).